# A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

> **NCT03366337** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 103 (actual)

## Conditions studied

- IgA Nephropathy
- CKD Associated With Type 1 Diabetes
- Focal Segmental Glomerulosclerosis
- Autosomal Dominant Polycystic Kidney

## Interventions

- **DRUG:** Bardoxolone methyl capsules

## Key facts

- **NCT ID:** NCT03366337
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-26
- **Primary completion:** 2019-01-02
- **Final completion:** 2019-01-29
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366337, "A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03366337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*